ZVRA Q1 2025 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+495.6% YoY

Gross Profit

$19M93.4% margin

Operating Income

-$5M-26.3% margin

Net Income

-$3M-15.2% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+69.4%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$173M

Total Liabilities

$132M

Stockholders' Equity

$41M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$3M	+495.6%
Gross Profit	$19M	$160,000	+11810.0%
Operating Income	-$5M	-$20M	+73.8%
Net Income	-$3M	-$17M	+81.4%